Background: Before kidney transplantation, a serological crossmatch is routinely performed between donor and recipient to prevent hyperacute rejection by donor-specific anti-human leukocyte antigen (HLA) antibodies. After transplantation, the presence of these antibodies is not routinely monitored. We wanted to know whether donor-specific anti-HLA antibodies are detectable during acute rejection (AR), before or after reduction of immunosuppression in kidney transplant recipients who were converted from cyclosporine A (CsA) to the less nephrotoxic azathioprine (AZA) or mycophenolate mofetil (MMF) at 1 year after transplantation.
Methods: Plasma samples were collected before transplantation, at several time points after transplantation, and during AR. Antibodies were measured in 29 patients: 5 patients with AR during the first year after transplantation (before conversion), 14 patients with AR after conversion or dose-reduction of AZA or MMF, and a control group of 10 patients without AR during a follow-up of 2 years (1 year before and 1 year after conversion of immunosuppression). Antibodies were measured by complement-dependent cytotoxicity assay, enzyme-linked immunosorbent assay (ELISA), and flow-cytometry in a crossmatch with donor spleen cells.
Results: Donor-specific antibodies were not detectable after transplantation in the control group without AR, nor in patients with AR shortly after transplantation during CsA therapy. After conversion from CsA to AZA or MMF, antibodies appeared only in one patient after graft failure followed by transplantectomy and in patients during AR on AZA but not on MMF therapy.
Conclusion: In this patient group, we could not detect donor-specific antibodies during CsA treatment, not even at the time of AR using three different techniques. Donor-specific antibodies were primarily present during AR in patients converted from CsA to AZA and were not found in the sera from patients converted to MMF.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.TP.0000054840.70526.D0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Myositis-Associated Interstitial Lung Disease: The Experience of a Tertiary Center.
J Clin Med
October 2024
Rheumatology Department, Unidade Local de Saúde Santa Maria (ULSSM), 1649-028 Lisbon, Portugal.
: Interstitial lung disease (ILD) is a common extra-muscular manifestation of idiopathic inflammatory myopathies (IIMs), often associated with a poorer prognosis and increased mortality risk. : This retrospective study aimed to characterize lung involvement and treatment response in an IIM cohort at a Portuguese tertiary center, followed between June 2016 and March 2024. We analyzed data from high-resolution computed tomography (HRCT) scans and pulmonary function tests (PFTs) to assess associations with autoantibody profiles and treatment regimens.
View Article and Find Full Text PDFEffectiveness and Safety of Mycophenolate Mophetil in Myasthenia Gravis: A Real-Life Multicenter Experience.
Brain Sci
July 2024
Department of Biomedicine, Neuroscience and Advanced Diagnostics (BIND), University of Palermo, 90127 Palermo, Italy.
Background: Myasthenia gravis (MG) is an autoimmune disease characterized by fluctuating muscle weakness due to autoantibodies targeting neuromuscular junction proteins. Mycophenolate mofetil (MMF), an immunosuppressive therapy, has shown potential for managing MG with fewer side effects compared to other treatments. This study aims to evaluate the effectiveness and safety of MMF in MG patients in a real-life multicenter setting.
View Article and Find Full Text PDFEfficacy of disease-modifying antirheumatic drugs in primary Sjögren's syndrome-related interstitial lung disease.
Med Clin (Barc)
November 2024
Akdeniz University School of Medicine, Department of Internal Medicine, Division of Rheumatology, Antalya, Turkey.
Objectives: To evaluate the treatment modalities and their effects in primary Sjögren's syndrome (pSS) patients with interstitial lung disease (ILD).
Methods: In this chart review study, patients diagnosed with pSS-related ILD (pSS-ILD) between January 2004 and August 2022 were screened. Glucocorticoid use and administered disease-modifying antirheumatic drugs (DMARDs) were determined.
Successful treatment of relapsed and refractory CIDP with ofatumumab: a first case report.
Front Immunol
August 2024
Department of Neurology, People's Hospital of Wuchuan County, Zunyi, Guizhou, China.
Background: Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a heterogeneous but treatable immune-mediated neuropathy. Ofatumumab (OFA) is a fully human anti-CD20 monoclonal antibody that has shown promising efficacy in central demyelinating diseases, such as multiple sclerosis (MS). However, there is a lack of studies on the usage of OFA in peripheral demyelinating diseases, particularly CIDP.
View Article and Find Full Text PDFTraditional first-line treatment failure rates in neuromyelitis optica spectrum disorder patients included in the Argentinean registry (RelevarEM).
Mult Scler Relat Disord
September 2024
Centro Esclerosis Múltiple Buenos Aires (CEMBA)Buenos Aires, Argentina.
Article Synopsis
- Immunosuppressive therapies like azathioprine (AZA), mycophenolate mofetil (MMF), and rituximab (RTX) are used to prevent relapses in NMOSD, but response rates specifically in Argentina were previously unknown.
- A retrospective study analyzed 139 NMOSD patients from the RelevarEM registry, tracking their response to these treatments over a mean follow-up of 41.3 months, revealing that RTX had a significantly lower treatment failure rate compared to AZA and MMF.
- The study found treatment failures were 42.8% for AZA, 40% for MMF, and only 10.3% for RTX, indicating that higher efficacy treatments like RTX
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!